Specifically in breast cancer, high expression of ALCAM occurs in approximately 50% of patients with triple-negative cancers and around 80% in patients with estrogen receptor positive, human epidermal growth factor receptor 2 (HER2) tumors (36). Here, ERBB2 is linked to breast carcinoma.